MarketFriction

Divis Laboratories Ltd

NSE DIVISLAB · BSE 532488 · Pharmaceuticals
₹9,249.00 -0.46%
NSE close2026-10-01
52 week range5,647.50 - 9,740.00
Market cap₹2,50,363 Cr.
P/E84.0
Nifty Next 50Nifty 100Nifty 200Nifty 500Nifty PharmaNifty Healthcare Index No price band Delivery 67.1%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Consolidated, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales1,9091,8552,3032,1182,3382,3192,5852,4102,7152,6042,8313,080
Expenses1,4301,3661,5721,4961,6221,5761,6991,6811,8271,7141,8971,825
Operating Profit4794897316227167438867298888909341,255
OPM %25%26%32%29%31%32%34%30%33%34%33%41%
Other Income8695797910682861191451415564
Interest102010138666
Depreciation959595979999107112113118120133
Profit before tax4694897136047227268647339127809631,180
Tax %26%27%25%29%29%19%23%26%24%25%22%24%
Net Profit348358538430510589662545689583751902
EPS in Rs13.1113.4920.2716.2019.2122.1924.9420.5325.9521.9628.2933.98
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales3,7764,0643,8914,9465,3946,9698,9607,7687,8459,36010,56011,230
Expenses2,3542,6152,6223,0723,5684,1025,0755,3975,6356,3877,1187,263
Operating Profit1,4231,4501,2691,8741,8262,8673,8852,3702,2102,9733,4423,967
OPM %38%36%33%38%34%41%43%31%28%32%33%35%
Other Income937210715418657112344335348433378
Interest53257222432426
Depreciation118123142169186256312343378402463484
Profit before tax1,3931,3951,2311,8551,8192,6663,6842,3692,1632,9163,3883,835
Tax %19%24%29%27%24%26%20%23%26%25%24%
Net Profit1,1261,0608771,3531,3771,9842,9601,8231,6002,1912,5682,925
EPS in Rs42.4139.9533.0450.9651.8574.75111.5268.6960.2782.5396.73110.18
Dividend Payout %24%25%30%31%31%27%27%44%50%36%31%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth11%9%11%16%
Compounded Profit Growth9%6%13%29%
Stock Price CAGR22%14%36%66%
Return on Equity18%17%15%17%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital275353535353535353535353
Reserves3,4694,2405,3045,8726,9047,2579,24211,67512,71413,51814,91616,708
Borrowings2742366310639543347
Other Liabilities8835627627979731,1831,4711,6281,6541,8861,9483,251
Total Liabilities4,4054,8986,1556,7858,0368,53110,77113,36014,42515,46016,92120,019
Fixed Assets1,3091,4391,5591,9962,0882,7823,7044,3254,7234,7395,4426,528
CWIP2182644441204929207114702127781,0222,113
Investments7338031,6311,8891,94697107277826569
Other Assets2,1452,3922,5212,7803,5113,8586,3568,4939,4139,86110,39211,309
Total Assets4,4054,8986,1556,7858,0368,53110,77113,36014,42515,46016,92120,019
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity8261,0381,1507769541,2161,9471,9122,4601,2611,6532,738
Cash from Investing Activity-521-406-1,140-478-685-8375-2,195-2,708-269-804-2,219
Cash from Financing Activity-303-6312-314-246-1,091-35-532-797-799-799-804
Net Cash Flow3013-1723411,987-816-1,04519350-285
Free Cash Flow519642774502221331,0371,1991,987258215221
CFO/OP88%91%100%82%77%91%90%66%124%74%83%105%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days878581958696889984100106103
Inventory Days350293307314347316329341352364311346
Days Payable6856104969610011796899488106
Cash Conversion Cycle368322284313336312300344347370330343
Working Capital Days140158147176169180152177188206192195
ROCE %33%36%29%22%29%25%32%35%19%16%20%22%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters51.93%51.92%51.92%51.89%51.89%51.89%51.89%51.88%51.88%51.88%51.88%51.88%
FIIs14.60%14.85%14.68%16.16%17.25%17.98%18.01%19.74%19.39%20.08%20.29%20.19%
DIIs21.65%21.78%22.10%21.66%20.98%20.44%20.63%18.96%19.68%19.18%19.13%19.29%
Government0.10%0.10%0.10%0.10%0.09%0.09%0.09%0.09%0.09%0.09%0.09%0.09%
Public11.72%11.33%11.19%10.17%9.79%9.58%9.39%9.32%8.96%8.75%8.61%8.53%
No. of Shareholders3,73,8603,54,4823,47,6292,98,3102,78,8992,80,6012,67,7552,59,8252,49,6342,33,8442,28,0062,26,324

Fundamentals

Market Cap₹ 2,50,363 Cr.
Current Price₹ 9,431
Stock P/E84.0
Book Value₹ 631
ROCE22.0 %
ROE16.5 %
Dividend Yield0.32 %
Face Value₹ 2.00
Compounded Sales Growth (TTM)16%
Compounded Profit Growth (TTM)29%
Consolidated figures.
Valuation
Market capRs 245,532 Cr
Enterprise valueRs 242,125 Cr
P/E (TTM)83.94x
Price to book14.65x
Price to sales21.86x
EV / EBITDA55.72x
EV / EBIT62.71x
EV / sales21.56x
Price to cash flow89.68x
Earnings yield1.19%
Dividend yield0.32%
P/E, 3-year average62.87x
P/B, 3-year average8.80x
P/E, 5-year average53.84x
P/B, 5-year average8.45x
Profitability
Operating margin (excl. other income)32.59%
Operating margin (incl. other income)36.70%
EBITDA margin38.69%
Pre-tax margin34.15%
Net profit margin26.05%
Net margin, latest quarter29.29%
ROE16.19%
ROCE21.50%
ROA13.90%
ROE, 3-year average14.56%
ROCE, 3-year average19.47%
ROA, 3-year average12.71%
ROE, 5-year average17.35%
ROCE, 5-year average22.56%
ROA, 5-year average15.16%
ROIC (approx.)21.91%
Tax rate24.20%
Other income / net worth2.58%
Growth
Sales growth (latest year)12.82%
Profit growth (latest year)17.21%
Sales CAGR, 3 years10.78%
Sales CAGR, 5 years8.67%
Profit CAGR, 3 years12.09%
Profit CAGR, 5 years5.29%
Sales growth QoQ8.80%
Profit growth QoQ20.11%
Sales growth YoY (latest quarter)27.80%
Profit growth YoY (latest quarter)65.50%
Per share
EPS (TTM)Rs 110.18
EPS (latest year)Rs 96.73
EPS (latest quarter)Rs 33.98
EPS, 3-year averageRs 79.85
EPS, 5-year averageRs 83.95
Book value per shareRs 631.37
Sales per shareRs 423.03
Cash flow per shareRs 103.14
Free cash flow per shareRs 8.32
Dividend per share (latest year)Rs 29.95
Dividend per share, 3-year averageRs 29.95
Dividend per share, 5-year averageRs 29.97
Dividends
Dividend payout30.96%
Dividend payout, 3-year average38.98%
Dividend payout, 5-year average37.50%
Efficiency
Asset turnover0.53x
Fixed asset turnover1.62x
Inventory turnover1.28x
Inventory days285 days
Debtor days103 days
Debtors turnover3.54x
Creditor days106 days
Cash conversion cycle343 days
Working capital days195 days
Leverage
Total debtRs 7 Cr
Cash and bankRs 3,414 Cr
Net debtRs -3,407 Cr
Debt to equity0.00x
Net debt / EBITDA-0.78x
Interest coverage148.50x
Current ratio (filing 2026-03-31)5.43x
Quick ratio (filing 2026-03-31)3.50x
Trade payables (filing 2026-03-31)Rs 1,211 Cr
Owners' fund to total sources83.73%
Debt to assets0.04%
Cash flow
Cash from Operating Activity (latest year)Rs 2,738 Cr
Cash from Investing Activity (latest year)Rs -2,219 Cr
Cash from Financing Activity (latest year)Rs -804 Cr
Net Cash Flow (latest year)Rs -285 Cr
Free cash flow (latest year)Rs 221 Cr
FCFE (approx.: FCF + change in debt)Rs 224 Cr
Cash from ops / profit, 5 years0.90x
Sales to cash flow3.86x
Statement figures
Net sales (TTM)Rs 11,230 Cr
Net sales (latest year)Rs 10,560 Cr
Sales (latest quarter)Rs 3,080 Cr
Operating profit excl. other income (latest year)Rs 3,442 Cr
Operating profit (latest quarter)Rs 1,255 Cr
Other income (TTM)Rs 378 Cr
EBITDA (TTM)Rs 4,345 Cr
PBDT (TTM)Rs 4,319 Cr
Profit before tax (TTM)Rs 3,835 Cr
Tax (latest year)Rs 820 Cr
Net profit (TTM)Rs 2,925 Cr
Net profit (latest year)Rs 2,568 Cr
Net profit (latest quarter)Rs 902 Cr
Depreciation (TTM)Rs 484 Cr
Depreciation (latest quarter)Rs 133 Cr
Interest (TTM)Rs 26 Cr
Cost of goods sold (latest year)Rs 5,063 Cr
Total expenditure (latest year)Rs 7,118 Cr
Total income (latest year)Rs 10,993 Cr
Share capitalRs 53 Cr
ReservesRs 16,708 Cr
Shareholders' fundsRs 16,761 Cr
Total assetsRs 20,019 Cr
Net blockRs 6,528 Cr
Capital work in progressRs 2,113 Cr
InvestmentsRs 69 Cr
ReceivablesRs 2,984 Cr
InventoryRs 3,954 Cr
Other liabilitiesRs 3,251 Cr
Shares outstanding (crore)26.55
Ownership
Promoter holding51.88% (+0.00 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/E 83.9 is at the 92th percentile of its own 9.4-year range (median 53.4, low 16.2, high 102.4).
P/B 14.65 is at the 94th percentile (median 8.39).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodDIVISLABNifty 50Difference
1 week-3.7%-2.8% -0.9 pts
1 month+0.9%-6.8% +7.7 pts
3 months+36.9%-7.6% +44.5 pts
6 months+55.5%+0.4% +55.1 pts
1 year+56.8%-9.9% +66.8 pts
2 years+72.1%-13.6% +85.7 pts
3 years+145.6%+14.2% +131.5 pts
5 years+91.4%+27.9% +63.5 pts
353 mutual fund schemes hold about ₹34,893 Cr. Over three months 98 bought more and 83 sold (share counts, price move removed).
FundWeightEst. Cr3m shares
SBI Large Cap Fundd3.49%1,924 +5%
SBI Aggressive Hybrid Fund2.03%1,799 -16%
HDFC Flexi Cap Fund1.58%1,793 +4%
SBI Focused Fund2.90%1,486 -3%
Axis ELSS-Tax Saver Fund2.71%886 -4%
HDFC Balanced Advantage Fund0.78%841 +4%
Nippon India Large Cap Fund1.51%815 +3%
Axis Large Cap Fund2.58%810 +4%
SBI Multicap Fund3.28%805 -6%
SBI Large & Midcap Fund1.86%786 +1%
Axis Focused Fund6.17%704 -10%
Nippon India Pharma Fund7.00%663 -6%
Mirae Asset Large & Midcap Fund1.39%638 +265%
Nippon India Multi Cap Fund1.12%632 +2%
HDFC Manufacturing Fund5.94%629 -3%
Kotak Arbitrage Fund(M0.70%529 -44%
ICICI Pru Nifty Next 50 Index Fund4.73%479 +1%
SBI Healthcare Opp Fund8.17%473 +1%
Axis Large & Mid Cap Fund2.66%461 +28%
HDFC Aggressive Hybrid Fund2.02%450 +0%
Axis Large & Mid Cap Fund2.66%448 +28%
Quant ELSS Tax Saver Fund3.31%445 +428%
UTI Flexi Cap Fund1.67%405 -0%
SBI Arbitrage Fund0.80%379 +4%
SBI MNC Fund5.64%379 -2%

Red flags

F-score 5 of 8
No red flags in the latest statements and filings.
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Insider trades

NSE insider and takeover-code disclosures
DateWhoRoleSideSharesValueHow
2026-02-26A. LakshmiImmediate relativesell500Rs 0.32 CrMarket Sale
2025-12-26Donepudi SitaImmediate relativeother500Rs 0.32 CrGift
2025-12-26P. Rama SekharEmployees/Designated Employeother500Rs 0.32 CrGift
2025-12-09SUDHEER KUMAR LINGAMNENIEmployees/Designated Employeother1,000Rs 0.63 CrGift
2025-12-09L. LakshmiImmediate relativeother1,000Rs 0.63 CrGift
2025-09-10S. RAMA KRISHNAEmployees/Designated Employeother2,500Rs 1.51 CrGift
2025-09-10S Krishna SreeImmediate relativeother7,500Rs 4.52 CrGift
2025-06-30K. SrideviImmediate relativesell150Rs 0.10 CrMarket Sale
2025-06-11K. SrideviImmediate relativesell400Rs 0.27 CrMarket Sale
2025-06-10Yalavarthi Vamsi KrishnaImmediate relativesell200Rs 0.13 CrMarket Sale
2025-05-27Ch. VenuEmployees/Designated Employesell150Rs 0.10 CrMarket Sale
2025-05-27G.KelithaImmediate relativesell150Rs 0.10 CrMarket Sale
Latest disclosed trades by insiders, promoters and large holders. Grants, option exercises and pledges show as "other". A filing is a fact, not a signal on its own.

Latest quarter

Jun 2026
Sales ₹3,080 Cr +27.8% vs Jun 2025. Net profit ₹902 Cr +65.5%.

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
Ipca Laboratories Ltd49,17035.817.0 %
No bulk or block deals on record.
Ex-dateActionFactor
2026-07-24Dividend - Rs 30 Per Share
2025-07-25Dividend - Rs 30 Per Share
2024-08-02Dividend - Rs 30 Per Share
2023-08-11Dividend - Rs 30 Per Share
2022-08-11Dividend - Rs 30 Per Share
2021-08-17 Dividend - Rs 20 Per Share
2020-09-04 Annual General Meeting
2020-02-25 Interim Dividend - Rs 16 Per Share
2019-08-14 Annual General Meeting/Dividend - Rs 16 Per Share
2018-08-31 Annual General Meeting/Dividend- Rs 10 Per Share
2017-09-15 Annual General Meeting/Dividend - Rs 10/- Per Share
2016-08-18 Annnual General Meeting
2016-03-17 Interim Dividend - Rs 10/- Per Share (Purpose Revised)
2015-09-23 Bonus 1:10.5000
2015-08-06Annual General Meeting/Dividend - Rs 20/- Per Share
2014-07-31Annual General Meeting / Dividend - Rs 20/- Per Share
2013-07-25Annual General Meeting/Dividend Rs 15/- Per Share
2012-07-26Annual General Meeting/ Dividend Of Rs. 13 Per Share
2011-06-16Annual General Meeting And Dividend Rs.10/- Per Share
2010-07-02Annual General Meeting And Dividend Rs.6/- Per Share
2009-07-30Bonus-1:10.5000
2009-06-15Agm/Div-Rs.6/- Per Share
2008-06-26Agm/Dividend - 200%
2007-08-03Agm/Fv Split Rs10 To Rs20.2000
2007-03-23Interim Dividend-100% Purpose Revised
2006-08-23Agm/Dividend-100%
DateTypeWhat it says
2026-08-10Shareholder meetingProceedings of Annual General Meeting held on August 10, 2026. Further, the company has submitted the Exchange a copy of Srutinizers report along with...
2026-08-06Concall / analyst meetTranscript
2026-08-01Concall / analyst meetLink of Recording
2026-08-01Change in ManagementChange in Senior Management.
2026-08-01Board meeting outcomeDivis Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-07-31RetirementRetirement of Senior Management Personnel.
2026-07-24Concall / analyst meetSchedule of meet
2026-07-15Shareholder meetingNotice of Annual General Meeting to be held on August 10, 2026
2026-07-06Disclosure under SEBI TakeovDivis Laboratories Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Su...
2026-06-11UpdatesInformation regarding deduction of Income tax at source from payment of Dividend for the financial year 2025-26.
2026-05-29Concall / analyst meetTranscript
2026-05-25Board meeting outcomeDivis Laboratories Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
2026-05-23Concall / analyst meetLink of Q4FY2026 earnings call audio recording.
2026-05-23Record DateRecord date for the purpose of Dividend is 24-Jul-2026.
2026-05-23DividendBoard of Directors at its meeting held on May 23, 2026, recommended Final Dividend of Rs. 30 per equity share.
2026-05-23Board meeting outcomeDivis Laboratories Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
2026-05-15Concall / analyst meetSchedule of earnings conference call.
2026-03-21LitigationDraft Order issued under Section 144C(1) of the Income Tax Act, 1961 for FY2022-23.
2026-02-14Concall / analyst meetTranscript
2026-02-11Concall / analyst meetLink of Recording
2026-02-11Board meeting outcomeDivis Laboratories Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
2026-02-03Concall / analyst meetSchedule of meet
2025-11-14General UpdatesUS-FDA Inspection of Company s Unit-I manufacturing facility
2025-11-12Concall / analyst meetTranscript
2025-11-07Concall / analyst meetLink of Recording
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
Put / call open interest0.59
Max pain (expiry 2026-10-27)9,500
Largest call open interest at10,000
Largest put open interest at8,500
Implied volatility, at the money23.9%
Underlying at snapshot9,249.00
Open interest by strike around the price, nearest expiry. End-of-day NSE snapshot, 01-Oct-2026 15:40:00. Max pain is the strike where option buyers together would lose the most at expiry.
Trade dateShares sold short
2026-09-29800
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Scrip PE is greater than 50 (4 trailing quarters)

Quick answers

What is the market cap of Divis Laboratories Ltd?

Divis Laboratories Ltd (DIVISLAB) has a market capitalisation of Rs 2,50,363 Cr. at the 2026-10-01 close.

What is the P/E ratio of Divis Laboratories Ltd?

Divis Laboratories Ltd trades at a P/E of 84.0 on trailing twelve-month profit, at the 2026-10-01 close.

What were Divis Laboratories Ltd's latest quarterly results?

In the Jun 2026 quarter, Divis Laboratories Ltd sales was Rs 3,080 Cr (+27.8% vs Jun 2025) and net profit was Rs 902 Cr.

What is the 52-week high and low of Divis Laboratories Ltd?

The 52-week high is Rs 9,740.00 and the 52-week low is Rs 5,647.50.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03